Douglas Fambrough - Aug 10, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role: President and CEO, Director
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Stock symbol: DRNA
Transactions as of: Aug 10, 2021
Transactions value $: $110,480
Form type: 4
Date filed: 8/10/2021, 08:06 PM
Next filing: Dec 13, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Purchase	$110K	+5K	+13.1%	$22.10	43.2K	Aug 10, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $22.035 to $22.11, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2	Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

Content

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $22.035 to $22.11, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).